<DOC>
<DOCNO>EP-0630248</DOCNO> 
<TEXT>
<INVENTION-TITLE>
USE OF ESTRIOL FOR THE MANUFACTURE OF A TRANSDERMAL THERAPEUTIC SYSTEM FOR TREATING CLIMACTERIC OSTEOPOROSIS
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31565	A61K970	A61P1900	A61K970	A61P302	A61P1910	A61P4300	A61K906	A61P4300	A61P300	A61K906	A61K31565	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61P	A61K	A61P	A61P	A61P	A61K	A61P	A61P	A61K	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K9	A61P19	A61K9	A61P3	A61P19	A61P43	A61K9	A61P43	A61P3	A61K9	A61K31	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The invention relates to the use of estriol as a single active agent for the production of a transdermal medicament continuously releasing the active agent for the treatment of climacteric osteoporosis. According ot the invention, it has been shown that estriol, which was formerly regarded as ineffective in treating climacteric osteoporosis, displays a strongly antiosteoporotic effect with continuous transdermal application.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
ENTEC
</APPLICANT-NAME>
<APPLICANT-NAME>
ENTEC GESELLSCHAFT FUER ENDOKRINOLOGISCHE TECHNOLOGIE M.B.H.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
DITTGEN MICHAEL
</INVENTOR-NAME>
<INVENTOR-NAME>
ELGER WALTER
</INVENTOR-NAME>
<INVENTOR-NAME>
ERNST MICHAEL
</INVENTOR-NAME>
<INVENTOR-NAME>
HUEBLER DORIS
</INVENTOR-NAME>
<INVENTOR-NAME>
OETTEL MICHAEL
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHNEIDER BIRGITT
</INVENTOR-NAME>
<INVENTOR-NAME>
DITTGEN, MICHAEL
</INVENTOR-NAME>
<INVENTOR-NAME>
ELGER, WALTER
</INVENTOR-NAME>
<INVENTOR-NAME>
ERNST, MICHAEL
</INVENTOR-NAME>
<INVENTOR-NAME>
HUEBLER, DORIS
</INVENTOR-NAME>
<INVENTOR-NAME>
OETTEL, MICHAEL
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHNEIDER, BIRGITT
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Use of estriol for the production of transdermal
therapeutic systems which release active ingredient

continuously for at least 24 hours for the treatment of
climacteric osteoporosis, the systems containing estriol as

sole active ingredient.
Use according to claim 1, characterized in that the
transdermal therapeutic system is a transdermal plaster.
Use according to claim 1, characterized in that the
transdermal therapeutic system is a transdermal emulsion

ointment.
Use according to claims 1 to 3, characterized in that the
transdermal therapeutic system contains 5 to 25 mg estriol

per dose unit.
</CLAIMS>
</TEXT>
</DOC>
